MEDICILON

contact us jpkrencn

お知らせ

企業動向

あなたはここにいる:ホーム > お知らせ > 企業動向 > Guangzhou Magpie Pha...

Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN08

著者:medicilon   アップロード:2020-02-26  閲読回数:

Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH). IPAH is a progressive disease that affects the precapillary pulmonary vasculature. IPAH is a rare and fatal disease which has a high mortality rate.

Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon

During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and development of the GMP manufacturing for API.

上の:Medicilon assisted PA1010 tablets with implied permission for clinical trials

下に:Previous Medicilon – Extraordinary “2 0 1 9”